News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Commercial Platform
Group
Innovation Platform
Regulatory Notice
12
3
456789101112
found Documents:568
London: Tuesday, October 24, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares (“ADSs”), each
Read more
– Data for savolitinib in combination with Tagrisso® or Iressa® presented at World Conference on Lung Cancer –  – New data give insights into disease progression and potential next-generation treatment strategies in patients with EGFR-muta
Read more
OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han
Read more
OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T
Read more
Press Release – Fruquintinib in combination with Iressa® (gefitinib) shows promising efficacy and an acceptable safety profile – – Further validation of strong potential for use of fruquintinib in combination with other cancer therapies du
Read more
JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA
Read more
Appointment of Director London: Thursday, October 12, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of t
Read more
Press Release   – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups
Read more
Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly
Read more
London: Friday, September 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 29, 2017, the issued share capital of Chi-Med consisted of 60,750,132 ord
Read more
Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,
Read more
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif
Read more
In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen
Read more
Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi,  Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei
Read more
Lotte New York Palace Hotel, New York, NY
The Landmark Hotel, London, UK Please visit live.ft.com for more information.
Read more
Island Shangri-La Hotel, Hong Kong
The Royal Society of Medicine, London, UK Please visit rsm.ac.uk for more information. A video recording of the 20-minute presentation is available. RSM video link Note: there is a 25-second audio error at 2:55.
Read more
London: Thursday, August 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated with Mr To,
Read more
Press Release London: Tuesday, August 29, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated a Phase I clinical trial of HMPL‑689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhib
Read more
London: Tuesday, August 22, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of
Read more
London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely
Read more
London: Tuesday, August 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (
Read more
Contents Corporate Information Inside Cover Contents 1 Highlights 2 Chairman’s Statement 8 Financial Review 10 Operations Review 12 Condensed Consolidated Balance Sheets 27 Condensed Consolidated Sta
Read more
London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of th
Read more
London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“P
Read more
London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob
Read more
Announcement released: 7am BST (2am EDT, 2pm HKT) » See announcement here Presentation webcast & call: 9am BST (4pm HKT) » click here for a video of the webcast US conference call: 9am EDT (2pm BST) » To parti
Read more
London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shar
Read more
AstraZeneca PLC (“AstraZeneca”) (LON/STO/NYSE: AZN) Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM)   London: Thursday, June 29, 2017: Chi-Med and AstraZeneca today announce that they have initiated
Read more
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited 2. Name of sc
Read more
London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana
Read more
Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur
Read more
Press Release London: Thursday, June 22, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL‑453 in China.  HMPL‑453 is a novel, highly selective and potent small mol
Read more
London: Friday, June 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Dynamic Drive Limited, a person closely associated (“PCA”) with Mr Simon To, Executive Director and Chairma
Read more
– Application accepted by CFDA for technical review by the Center for Drug Evaluation – – Triggers RMB30.8 million milestone payment from Eli Lilly and Company (“Lilly”) – London: Monday, June  12, 2017: Hutchison China MediTech L
Read more
Press Release Chicago: Monday, June 5, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that results from its pivotal Phase III trial with fruquintinib, its novel vascular endothelial growth factor receptor (“VEGF
Read more
A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol
Read more
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti
Read more
Press Release – FRESCO Phase III trial results for fruquintinib in colorectal cancer in an oral presentation – – Five abstracts in total accepted for fruquintinib, savolitinib and sulfatinib – London: Thursday, May 18, 2017: Hutchison Chin
Read more
London: Friday, April 28, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 28, 2017, the issued share capital of Chi-Med consisted of 60,735,104 ordinary sh
Read more